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arlier this year, Richard Smith, 
former editor of the BMJ and 
a current member of the PLoS 
board of directors, provocatively 
suggested that “journals should perhaps 
stop publishing trials. Instead, the 
protocols and results should be made 
available on regulated Web sites” (DOI: 
10.1371/journal.pmed.0020138). 
In the spirit of Smith’s suggestion, 
we are launching PLoS Clinical Trials 
(http:⁄⁄www.plosclinicaltrials.org), a 
new “regulated Web site” (which we’re 
still calling a journal) for peer-reviewed 
clinical trial reports.
We and the international advisory 
board believe this new journal is an 
important step toward overcoming 
publication bias, whereby published 
research differs systematically from 
unpublished data in its direction and 
strength of ﬁ  ndings. Research funded 
by drug companies, for example, is less 
likely to be published than research 
funded by other sources (BMJ 326: 1167–
1170), and roughly half of all completed 
trials are believed to go unpublished 
(AIDS Educ Prev 9 [Suppl 1]: 15–21). 
Clearly, bias in the published literature 
distorts the evidence available for other 
researchers, systematic reviewers, and 
ultimately for clinical decision making by 
health professionals and patients.
As we have previously argued (DOI: 
10.1371/journal.pmed.0010046), 
many safeguards are needed to ensure 
a transparent trial reporting system, 
and PLoS Clinical Trials is just one 
such initiative. Universal prospective 
registration of trials in a publicly 
accessible repository is a crucial 
mechanism for ensuring that trials are 
known about at the start, to uniquely 
identify them and to reveal the 
existence of unpublished trials. Trial 
registration has gained widespread 
support from the major medical 
journals (JAMA 293: 2927–2929), and is 
currently the subject of a bill before the 
United States Congress (the Fair Access 
to Clinical Trials Act). 
Two other initiatives include sponsors 
publicly releasing trial data on their 
own Web sites (BMJ 330: 479–480), and 
the US Food and Drug Administration 
posting selected review documents 
for new drug approvals on its Web site 
(DOI: 10.1371/journal.pmed.0010060). 
However, it is difﬁ  cult to have 
conﬁ  dence in data released by sponsors 
when the data have not been subjected 
to external, independent peer review. 
Furthermore, this information is not 
integrated with other data, or indexed. 
PLoS Clinical Trials will be an 
unbiased venue for publication of 
trial data. The journal will peer review 
and publish the results of human 
clinical trials in all disciplines, and, 
crucially, direction of results, size, 
or signiﬁ  cance will be no barrier to 
publication. Only an open-access 
journal could provide the business 
model for this type of publication. As 
an online, open-access journal that 
does not have to sell subscriptions 
or reprints to survive, PLoS Clinical 
Trials can consider all reports of trials 
that meet predetermined ethical and 
scientiﬁ  c criteria. 
The rationale for open access to 
clinical trial data is overwhelming: many 
parties, from researchers to clinicians, 
meta-analysts to policymakers, have a 
need to read, analyze, and manipulate 
such data. Above all, patients who have 
altruistically volunteered to participate 
in trials want to be assured that the data 
are freely and publicly available for the 
beneﬁ  t of others.
PLoS Clinical Trials will be online only. 
Each article will be cross-linked with 
trial registry records, such as those of 
ClinicalTrials.gov and the International 
Standard Randomised Controlled 
Trial Number (ISRCTN) Register. The 
inclusion of a trial identiﬁ  er with every 
paper enables users to see clearly which 
results belong to which trial; without 
a straightforward way of identifying 
duplicate papers, treatment effects can 
be signiﬁ  cantly overestimated. PLoS is 
collaborating with the Global Trial Bank 
(http:⁄⁄www.globaltrialbank.org), which 
is being developed by the American 
Medical Informatics Association, and 
which will ultimately ensure that trial 
data can be archived in a format that 
will allow scientists to analyze data 
across trials and, hence, generate new 
ﬁ  ndings and insights (10.1371/journal.
pmed.0020365).
We intend to go beyond CONSORT 
(a tool developed to improve the 
quality of reporting of randomized 
trials; http:⁄⁄www.consort-statement.
org/), asking authors to not only 
submit a CONSORT checklist and ﬂ  ow 
diagram, but also to organize their 
papers according to the CONSORT 
structure. Readers will be able to 
quickly identify where in the paper 
they need to look to ﬁ  nd out about a 
particular aspect of the design.
Rather than making 
recommendations about acceptance 
or rejection, peer reviewers of papers 
submitted to PLoS Clinical Trials will be 
asked to focus on improving the quality 
and transparency of trial reporting. 
Each trial report will be accompanied 
by an editorial summary of its strengths 
and weaknesses, including what it 
adds to current scientiﬁ  c knowledge. 
Readers will have the opportunity to 
post comments.
We offer unbiased reporting of 
results, but with rigorous external 
peer review, worldwide access free of 
barriers, and reports that are integrated 
with trial registries. We call on trial 
sponsors and investigators around the 
globe to support these goals. Pioneering 
authors should submit their work at 
http:⁄⁄www.plosclinicaltrials.org⁄.  
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